




Navarra Health Cluster

The largest alliance in
health and bioscience
in Navarre

CATALOGUE OF PARTNERS
2026



NHC

NAVARRA
HEALTH
CLUSTER

Content Index

NAVARRA HEALTH CLUSTER AT A GLANCE	4
HEALTH SECTOR AND INNOVATION IN NAVARRE	6
NHC VALUE CHAIN	9
Knowledge and R&D	11
Business segments:	21
Biopharma	22
MedTech	40
Services	68
Distribution	76
Care	81
Stakeholders	91

NAVARRA HEALTH CLUSTER AT A GLANCE

The largest alliance in health and bioscience in Navarre


Navarra Health Cluster is a private non-profit association that brings together companies and entities covering the entire value chain of the healthcare sector in Navarre (Spain).

Founded in October 2022, it currently brings together 67 associated entities, including 52 companies representing different business segments (biopharmaceutical industry, healthcare technology industry, services and distribution), seven knowledge centers, four professional associations and four healthcare centers.

It is supported by the Government of Navarre, as well as by Sodena (the financial support instrument of the Government of Navarre) and CEIN (European Business Innovation Center of Navarre), and is also part of the SINAI (Navarre R&D&I System) network of agents and the Alliance of Spanish Health and Biosciences Clusters (ACESABIO).

The main objective of Navarra Health Cluster is to actively promote knowledge, public-private collaboration, technology transfer, innovation and competitiveness of all the agents of the ecosystem.

Get to know us! www.navarrahealthcluster.com



67 PARTNERS

52 COMPANIES
of which:

2 PUBLIC
COMPANIES

6 LARGE
COMPANIES

45 SMEs, of
which 22 are
start-ups

2,500M€ OF TURNOVER. Which represents approximately 11% of Navarre's GDP.

2.500 M

17.800 PEOPLE of which +10,200 are in Navarre.

17.800

HEALTH SECTOR AND INNOVATION IN NAVARRE

The health sector is one of the areas of specialization of the region of Navarre and stands out as a booming sector.


As a result of the impetus and entrepreneurial efforts of business people and specialists, and with the support of the administrations, the region has achieved a very prominent position at international level in areas such as biotechnology, food chemistry and pharmaceuticals.

Navarra is classified as a “Strong Innovator” according to the Regional Innovation Scoreboard (RIS) 2023, with a score of **116,3 points**. It is **above the European average** and in Spain only the Basque Country, Madrid, Catalonia have this category too. This index evaluates scientific production, the generation of technology-based companies, digital skills, quality of life, educational level of the population, R&D spending, patents, innovation... Although it is not a sector-specific index, this value shows Navarre’s position as an innovative ecosystem, a creator of well-being, wealth and employment.

REGIONAL INNOVATION SCOREBOARD (RIS)

Summary innovation index in 2025 (relative to EU in 2018).

Catalunya/Cataluña
País Vasco
Comunidad de Madrid
Comunidad Foral de Navarra
Comunitat Valenciana
EU
Galicia
Aragón
Castilla y León
Cantabria
La Rioja
Región de Murcia
Principado de Asturias
Andalucía
Illes Balears
Castilla-La Mancha
Canarias
Extremadura
Ciudad de Ceuta
Ciudad de Melilla



The Navarre biosanitary industry*1:
Currently EXCEEDS:

80 COMPANIES
EMPLOYS more than
31.000 PEOPLE

And has increased its TURNOVER by
20% Since 2016


* According to the CEIN report (“Situación actual del sector salud en Navarra” elaborated in 2020).
According to the website:
www.investinnavarra.com/salud/



NHC VALUE CHAIN

Navarra Health Cluster fosters collaboration between different actors in the sector with a value chain approach, where knowledge generators drive the market (market push), the care sector as a whole demands new solutions

(market pull) and the different business segments channel knowledge to the market. This collaboration strengthens the business ecosystem and contributes to greater cohesion and synergy in the health sector in Navarre.



Some of the associated entities belong to more than one sector of the value chain.

Knowledge and R&D

Index of associated entities within the value chain:

	
Knowledge and R&D	11
Cima Universidad de Navarra	12
IdiSNA	13
Instituto de Agrobiotecnología (IDAB-CSIC)	14
NAIR Center	15
Navarrabiomed	16
Universidad de Navarra	17
Universidad Pública de Navarra	18
	
Business segments	21
	
Care	81
	
Stakeholders	91



Cima Universidad de Navarra

Research to heal



KNOWLEDGE AND R&D

Nº OF EMPLOYEES: 250–500

RESEARCH	TRANSLATION	THERAPY	INNOVATION
----------	-------------	---------	------------



Cima
Universidad
de Navarra

The Cima Universidad de Navarra was inaugurated in 2004 with the mission to carry out translational research of excellence oriented to the benefit of patients and society.

Its scientific objective is to address current clinical problems and to propose the most effective treatment for each patient. It is a leader in cancer research, liver and rare diseases and in advanced therapies such as immunotherapy, gene therapy, DNA and RNA medicine and biomedical engineering.

The high specialization of its professionals in different biomedical areas is reflected in the research quality of their scientific publications and the development of therapeutic innovations.

To transfer the results of basic research to clinical application, Cima has a Translation and Innovation unit which, in its commitment to open innovation, seeks to establish collaborations with biotechnology and pharmaceutical companies to facilitate the arrival of scientific discoveries to the patient.

Research at Cima is multidisciplinary, carried out by teams of professionals from different fields (biologists, biochemists, pharmacists, engineers, physicians, laboratory technicians, etc.) and in collaboration with other national and international centers.

In this context, in coordination with the Clínica Universidad de Navarra, synergies are favored with other professionals from other centers of the biomedical and technological campus of the University of Navarra, as well as with professionals from the University Hospital of Navarra and Navarrabiomed, within the framework of the Navarra Health Research Institute (IdiSNA).

CONTACT:

Avenida Pío XII 55 | E-31008 Pamplona – España | www.cima.cun.es | (+34) 948 194 700



IdiSNA

A space for multidisciplinary and translational
biomedical research



KNOWLEDGE AND R&D

Nº OF EMPLOYEES: 1–10

R&D&I	EXCELLENCE	BIOMEDICINE	INTEGRATION
-------	------------	-------------	-------------



CARE



Navarra Institute for Health Research (IdiSNA) is a multidisciplinary and translational biomedical research space, which has as its core the University Hospital of Navarra (HUN) and is oriented to basic, clinical, epidemiological and health services research. This Institute is the result of a partnership between research groups from the University Hospital of Navarra (HUN), the University Clinic of Navarre (CUN), Public University of Navarre (UPNA), University of Navarre (UN), Navarrabiomed (NB), the Center for Applied Medical Research (CIMA), the Institute of Public and Labor Health (ISPLN) and Primary Care of the Navarra Health Service (AP-SNS).

IdiSNA has been accredited by the Carlos III Institute of Health (ISCIII) as a Health Research Institute since January 24, 2019. Recently, in January 2024 it has renewed its accreditation as an IIS for another five years.

Unlike accredited institutes in other autonomous communities, IdiSNA has some unique characteristics. On the one hand, it covers the vast majority of biosanitary researchers in Navarre and, therefore, has a very relevant integrating character to achieve joint efforts with common objectives. On the other hand, it includes all the public and private health, research and university institutions in Navarre. It is also part of the SINAI and the Navarra Health Cluster, collaborative structures that allow scientific results to be brought together with the industrial fabric of Navarre, to improve their exploitation and commercialization.

CONTACT:

Recinto del Hospital Universitario de Navarra
C/ Irunlarrea, 3 | 31008 Pamplona, España | www.idisna.es/portal/ | info.idisna@navarra.es | (+34) 848 428 700



Instituto de Agrobiotecnología (IDAB-CSIC)

Biotechnology for One Health



KNOWLEDGE AND R&D			
Nº OF EMPLOYEES: 11-50			
INVESTIGATION	INNOVATION	KNOWLEDGE	BIOTECHNOLOGY



The Institute of Agrobiotechnology (IdAB-CSIC) is the only Research Institute of the Spanish National Research Council in the region of Navarre, and shares ownership with the Government of Navarre.

The IdAB-CSIC houses approximately 50 people organized into the areas of Administration and Project Management, Research Support Service, and two Scientific Departments with a range of multidisciplinary research groups led by 11 principal investigators. Scientific staff in the research groups includes both PhD students and Doctors, with a good equilibrium between training and senior scientists.

The research projects being developed at the IdAB-CSIC are devoted to generate cutting-edge knowledge, and to develop next-generation biotechnological tools to meet a whole range of current and future social challenges. These projects are conceived and undertaken to achieve integrative solutions framed within the “One Health” concept, to reduce the impact of infectious diseases and antimicrobial resistance in human, animal and environmental health,

to increase food production and quality based on sustainable agriculture by also mitigating the deleterious effects of climate change, and to promote healthy living habits directed to maintain human microbiota homeostasis aligned with our immune system. The relevance and quality of its investigations are reflected in a wide number of active projects funded by regional, national and European calls, resulting in high-impact scientific production and in the development of new technologies applicable to different productive sectors.

The IdAB-CSIC’s research areas in the biosanitary field stand out in:

- Antimicrobial resistance
- Microbial persistence in the environment
- Dysbiosis and disease
- Zoonoses and food safety

CONTACT:



NAIR Center

Driving the future of Artificial Intelligence



KNOWLEDGE AND R&D			
Nº OF EMPLOYEES: 1-10			
RESEARCH	COORDINATION	SPECIALIZATION	ARTIFICIAL INTELLIGENCE



The Navarra Artificial Intelligence Research Center (NAIR Center) is born with the aim of ensuring basic and applied, cross-cutting, and excellent research in Artificial Intelligence (AI) that accelerates the process of development and digital transformation of the industrial fabric and public administrations, directly benefiting the citizens of the Autonomous Community of Navarre.

Although it is based in Navarre, its scope of action is broad, covering not only the regional level, but also the national and international levels.

Its main objectives are:

- Promote high-quality research in artificial intelligence and data technology, both at the basic and applied levels, with relevance to society and the global scientific community.

- Disseminate knowledge in artificial intelligence, targeting businesses and society at large.
- Drive the use of artificial intelligence in the Navarre Innovation System and in regional businesses to enhance their competitiveness.
- Support academic research in artificial intelligence at universities and applied research in research and technological centers, seeking integration into the Digital Innovation Hub, promoting collaboration with the Navarre R&D&I System and universities.
- Promote the creation of high-value-added jobs and attract talent to Navarre in the field of artificial intelligence and data engineering.
- Contribute to the overall development of R&D&I and promote the creation of new technology companies and research centers in Navarre and neighboring regions.

CONTACT:



Navarrabiomed

Research is progress



KNOWLEDGE AND R&D			
Nº OF EMPLOYEES: 51-250			
RESEARCH	TRASLATION	THERAPY	INNOVATION



Navarrabiomed is a public biomedical research center created by the Government of Navarre’s Department of Health in 2012. Its mission is to promote, facilitate and perform leading-edge biomedical research to develop and implement innovative therapies that improve the quality of public healthcare. In 2016, it became a joint center with the Public University of Navarre.

The center is currently organized in 20 research units and six technical and scientific services to promote scientific research and technological development: Biobank, Clinical Trials, Methodology – Health Services Research, Proteomics, Animal Lab and Experimental Operating Theater, and the CellMa Clean Room for Advanced Therapies. A total of 140 researchers are involved providing these services and research. Through its support units, Navarrabiomed facilitates and promotes research carried out by more than 250 healthcare professionals from other public centers in the region.

Miguel Servet Foundation

The Miguel Servet Foundation is the agency that has managed the activity of the biomedical research center Navarrabiomed since its establishment. In addition, it serves as a scientific and technical support platform for the development of research, innovation and training activities targeted at professionals in the public health administration.

CONTACT:



Universidad de Navarra

A commitment to research with a social focus and impact



KNOWLEDGE AND R&D			
Nº OF EMPLOYEES: > 1.000			
TEACHING	RESEARCH	EXCELLENCE	INTERNATIONALIZATION



Universidad de Navarra

Innovative teaching, impactful and interdisciplinary research, entrepreneurship, social and environmental responsibility and internationalization.

These are some of the main axes of the University of Navarra’s educational project aimed at the integral formation of students, both academically, culturally and personally, as well as at the development of society.

The University of Navarra fosters an international environment by attracting students from other countries, which currently makes up 29% (3920 students of 115 nationalities). The objective is for students to grow in a global context and to have an experience that allows them to work in any country.

CONTACT:



Universidad Pública de Navarra

Shared knowledge



KNOWLEDGE AND R&D			
Nº OF EMPLOYEES: > 1.000			
TRAINING	RESEARCH	KNOWLEDGE	COMMITMENT



The Public University of Navarre (UPNA) was founded in 1987 by the Parliament of Navarre, and has campuses in Pamplona and Tudela. It develops its academic activity in all the areas of knowledge: Engineering, Sciences, Health Sciences, Social and Legal Sciences and Arts and Humanities.

UPNA is committed to Navarre’s sustainable development and its culture through the generation, dissemination and transfer of knowledge, whole education of people and culture promotion within a free-thinking and open environment. UPNA is a key piece in Navarre’s researching activity, organised around research institutes, university-companies chairs and spin-offs foundation.

It counts on a researching community of over 1,000 people and, with its commitment to competitiveness,

UPNA has created 6 research institutes which gather over 500 of these people: Institute of Smart Cities (ISC), Institute for Advanced Materials and Mathematics (INAMAT²), Institute for Advanced Research in Business and Economics (INARBE), Institute for Sustainability & Food Chain Innovation (ISFOOD), Institute for Advanced Social Research (I-COMMUNITAS) and Institute for Multidisciplinary Research in Applied Biology (IMAB), aiming at tackling complex projects in a multidisciplinary way.

It is also part of Navarrabiomed, a biomedical research center of the Government of Navarre and the UPNA, and of the Institute for Health Research of Navarra (IdiSNA), a multi-disciplinary and translational biomedical research center.

CONTACT:

Campus de Arrosadía Arrosadía, s/n | 31006 Pamplona | (+34) 948 169 000 | oficina.informacion@unavarra.es
Campus de Salud, Avda. Barañain, s/n | 31008 Pamplona | (+34) 948 166 194 | www.unavarra.es/portada



Index of associated entities within the value chain:

 Knowledge and R&D	11
--	----

 Business segments	21
--	----

BIOPHARMA:		MEDTECH:		SERVICES:		DISTRIBUTION:	
Ametis Biotechnology	22	Abanza	40	Agenor Mantenimientos	41	Auxilab	76
Ardena	23	Agenor Mantenimientos	41	Ardena	23	Disayt	77
Bionanoplus	24	Bioinnovación Dental	42	Asphalion	68	Nafarco	78
Cinfa	25	Cinfa	25	Conasa	69	Sanifarma	79
Genbioma	26	Conasa	69	Data Value Management	45		
InnoUp Pharma	27	Creo Medical	43	EAA Med Consulting	70		
Medibiofarma	28	Darwin Biomed®	44	Hemotic	49		
MIMO Biosciences	29	Data Value Management	45	Hyssogenix	50		
Nanogrow Biotech	30	Embega Healthcare	46	IDEA Living Lab	88		
New Pharma Solutions	31	Erabaki 2010	47	Koümer	71		
Ojer Pharma	32	everSens	48	MyVitale	54		
Palobiofarma	33	Hemotic	49	NASERTIC	72		
Qube Pharma Group	34	Hyssogenix	50	New Pharma Solutions	31		
Recombina Biotech	35	IAR	51	Qube Pharma Group	34		
Telum Therapeutics	36	Insaight	52	Sumanlab	73		
Trimerbody Pharma	37	Medical Open World	53	Tairel Data	60		
V Labs Analytics	38	MyVitale	54	V Labs Analytics	38		
		NNBi	55				
		Opportunity Health	56				
		Orisnova	57				
		ORP - Online Rehabilitation	58				
		Program					
		OSF Plastics	59				
		Qube Pharma Group	34				
		Tairel Data	60				
		Tecnimoem	61				
		TedCas	62				
		Viscofan	63				
		Vitio	64				
		Ysium Medical	65				

 Care	81
---	----

 Stakeholders	91
---	----

Business segments:
 Biopharma, medtech, services
 and distribution



Amets Biotechnology

Innovative solutions for rare pediatric diseases



BUSINESS SEGMENTS: Biopharma			
Nº OF EMPLOYEES: 1-10			
ADVANCED THERAPIES	RARE DISEASES	PEDIATRIC DISEASES	R&D



Amets Biotechnology is a biotechnology company founded in 2025 dedicated to developing innovative gene therapies for rare pediatric diseases, created with the commitment to offer curative options to children facing severe conditions with no effective therapeutic alternatives.

Its purpose goes beyond scientific advancement: it seeks to generate meaningful social impact by transforming the prognosis and quality of life of pediatric patients and their families. Built on a strong scientific foundation and led by a team internationally recognized for its leadership in gene therapy, the company combines technological excellence, strategic vision, and translational expertise to accelerate the delivery of innovative therapeutic approaches into the clinical setting.

Its work focuses on designing high-precision therapeutic solutions, leveraging advanced platforms and specialized knowledge to maximize the safety, efficacy, and feasibility of its developments. Amets directs its efforts toward rigorous preclinical validation and clinical trial readiness, building a robust pipeline aimed at reshaping the therapeutic paradigm for rare pediatric diseases.

The combination of scientific innovation, global outlook, and social commitment positions the company as an emerging reference in advanced therapies, dedicated to bringing hope and real solutions to those who need them most.

Ardena

Navigating you through drug development



BUSINESS SEGMENTS: Biopharma and Services			
Nº OF EMPLOYEES: 501-1.000			
CDMO	DRUG PRODUCT	EARLY CLINICAL PHASES	HIGH POTENT DRUGS



Ardena, a fully integrated Contract Development and Manufacturing Organization (CDMO), is dedicated to assisting companies in developing innovative drugs and advancing their molecules into clinical trials.

Operating across five facilities throughout Europe, it provides a comprehensive range of services spanning from the development and manufacturing of the active substance and drug to the compilation of the quality module of the dossier and the analysis of biomarkers from clinical trials.

Its expertise lies in pharmaceutical product development and manufacturing across all phases, with a focus on enhancing bioavailability and capabilities in handling controlled substances and High Potency Active Pharmaceutical Ingredients (HPAPI).

Additionally, we offer comprehensive services in the development and manufacturing of pharmaceutical products, along with expertise in logistics and packaging for clinical trials. Ardena offers robust regulatory support in Chemistry, Manufacturing, and Controls (CMC), and excels in the development and manufacturing of nanomedicines.

At its Pamplona facility, a qualified team of over 100 professionals handles the development and manufacturing of solid oral dosage forms for both clinical development and commercial use. The facilities include dedicated spaces for handling high-potency substances and controlled substances.

Bionanoplus

Innovative solutions in nanoencapsulation



BIONANOPLUS
DRUG DELIVERY TECHNOLOGIES



BUSINESS SEGMENTS: Biopharma

Nº OF EMPLOYEES: 1-10

NANOTECHNOLOGY	DRUG DELIVERY	TECHNOLOGICAL INNOVATION	BIOTECH
----------------	---------------	--------------------------	---------

Bionanoplus is drug delivery biotechnological company founded in 2010 specialized in providing polymeric nanoencapsulation solutions.

Bionanoplus has solved the scalability problem of traditional nanoparticle manufacturing methods avoiding the use of volatile organic solvents, thus ensuring an easy and cheap production at any scale that can be performed using standard equipment and techniques. Bionanoplus has developed several proprietary technology platforms to obtain nanoparticle-based systems without using volatile organic solvents. The main advantages are:

- Its systems maintain the polymeric nanoparticles potential: increased bioavailability, controlled release, and enhanced solubility and stability.
- No volatile organic solvents means no special equipment or techniques to eliminate the common industrial scale-up issues decisive in many project failures which, together with a low cost of goods, ensures a cost-effectiveness production.
- All raw materials comply with the regulatory requirements and are commercially available.

Cinfa

Cinfa, health solutions in all fields





BUSINESS SEGMENTS: Biopharma and MedTech

Nº OF EMPLOYEES: > 1.000

PHARMACEUTICAL	HEALTH & WELLNESS
----------------	-------------------

Cinfa is a pharmaceutical company with 100% Spanish capital and almost 60 years' experience, specialising in the development, manufacture and marketing of medicines and health solutions. It offers patients prescription and over-the-counter (OTC) medicines, mobility and orthopaedic products, personal care treatments and scientifically backed natural solutions.

Its extensive vademecum and the quality, efficacy and safety of its treatments have made Cinfa the leading laboratory in terms of medicines dispensed in Spanish pharmacies, and therefore the most present in Spanish homes, with an average of ten treatments per household. Cinfa's solutions are also available in 120 countries worldwide, meeting the regulatory requirements and patient needs of each of these regions.

At Group level, Cinfa has a team of more than 2,300 professionals, four manufacturing plants and two R&D centres in Spain.

Over the past decade, the company has invested €487 million in R&D and infrastructure to strengthen medicine manufacturing capacity in Spain and ensure that all patients have access to the medicines they need.

It is thus committed to sustainable growth, which in recent years has taken shape in its diversification and internationalisation strategy and in the expansion of its facilities. It also launches an average of 100 new treatments each year, developed by its R&D team in collaboration with more than 80 research centres and universities in Spain and abroad.

Genbioma

Microbiome products to improve human health



BUSINESS SEGMENTS: Biopharma			
Nº OF EMPLOYEES: 1-10			
MICROBIOME	PROBIOTICS	POSTBIOTICS	HEALTH



Genbioma is a biotechnology research and development company for innovation in health care, focused on the international market thanks to the pioneering development of a new generation of Probiotics and Postbiotics. Its mission is simple: to improve people’s health through microbiome products.

The microbiome has exponential applications on health. Therefore, its cutting-edge technology allows the rapid identification of safe and effective bacterial strains and their mechanism of action. Genbioma already has a platform that has allowed the industrial development of a first range of patented microbiome products with scientific evidence of their safety and efficacy for people with diabetes and obesity.

The portfolio of microbiome solutions is in the form of probiotic and postbiotic food ingredients (pA1c®, pA1c®HI), and nutritional supplements (Reglubetic® and Reglubetic®HI). Genbioma has already started its positioning in the international market of postbiotics for the food industry and the OTC pharma channel.

InnoUp Pharma

Innovation Makes Us Better



BUSINESS SEGMENTS: Biopharma			
Nº OF EMPLOYEES: 1-10			
INNOVATIVE DRUG DEVELOPMENT	NANOTECHNOLOGY	IMMUNOTHERAPY	CANCER



InnoUp Farma is a Spanish clinical-stage biotechnology company founded in 2013 as a spin-off from the Nanomedicine Group at the University of Navarra. InnoUp develops oral therapies based on a proprietary technology platform that harnesses the body’s natural mechanisms, including those associated with the gut microbiota, to optimize drug performance and improve efficacy and safety. The technology enables drugs to be protected from degradation within the gastrointestinal tract, while enhancing their absorption and bioavailability, modulating immune responses, and enabling controlled access to the lymphatic system following oral administration. With a team combining scientific expertise, pharmaceutical development capabilities, and business strategy, InnoUp aims to translate its technology into novel therapeutic solutions while building strategic partnerships to accelerate development and international expansion.

InnoUp currently has two clinical-stage assets demonstrating the potential of its technology platform across different therapeutic areas. INP20 is an oral immunotherapy for peanut allergy, designed to promote the development of immune tolerance by educating the immune system through the intestinal mucosa. INP12 is an oral paclitaxel-based chemotherapy developed to improve oral drug delivery and enable controlled access to the lymphatic system.

InnoUp’s key competitive advantage lies in its ability to harness the body’s natural mechanisms to improve the performance of a broad range of drugs. The platform combines drug protection, enhanced absorption and bioavailability, immune modulation, and lymphatic targeting. Its versatility enables the company to address different drug types and diseases through a single proprietary technology platform, supported by a scalable continuous manufacturing process designed for GMP production. This positioning allows InnoUp to operate not only as a drug developer, but also as a technology partner for pharmaceutical and biotechnology companies seeking to apply the platform to new therapeutic programs.

InnoUp’s objective is to establish its technology platform as a differentiated solution for the development of oral therapies, progressively expanding its application across different drugs and therapeutic areas. The company is focused on advancing its clinical programs and generating clinical evidence to validate the platform’s potential and maximize the value of its assets. In parallel, InnoUp aims to accelerate its growth through strategic agreements with pharmaceutical and biotechnology companies, investors, and international industrial partners, pursuing licensing, co-development, and strategic partnership models.

Mediobiofarma

Innovative target-based medicinal chemistry



BUSINESS SEGMENTS: Biopharma			
Nº OF EMPLOYEES: 1-10			
BIOTECH	MEDICINAL CHEMISTRY	SMALL MOLECULE	DRUG DISCOVERY



Mediobiofarma is a clinical-stage biotechnology company founded in 2016 by a group of professionals with extensive experience in new drug discovery and the pharmaceutical industry.

Its goal is to generate innovative and high quality research programs based on the modulation of clinically validated therapeutic targets for the treatment of diseases of high medical need.

It is currently developing 3 research programs in which it has selected three candidates that are in the clinical phase.

Mediobiofarma is based in the European Business and Innovation Center (CEIN) in Noáin, Navarra, where it shares a 200 m2 laboratory and performs the tasks of direction, management and medicinal chemistry. All other activities, such as preclinical studies, pharmaceutical development and Phase I and Phase IIa clinical trials, are carried out through a wide network of collaborators.

MIMO Biosciences

Excellence in services based in science



BUSINESS SEGMENTS: Biopharma			
Nº OF EMPLOYEES: 1-10			
SERVICES	ONCO-HEMATOLOGY	SCIENCE DRIVEN	EXCELLENCE



MIMO Biosciences is a spinoff of Cima Universidad de Navarra that provides services to pharmaceutical companies in the field of onco-hematology and immunotherapy.

The services provided are mainly in the field of research, especially in preclinical phases, and are based on unique animal models that cover a wide range of genetic and immunological alterations of different hematological malignancies.

The models developed by the MIMO's team for more than ten years provide invaluable insights to pharmaceutical companies in their drug development process,

advancing key aspects of tumor biology. The models can bring out key data on the efficacy and toxicity of tested drugs, which allows an optimized decision making process saving time and reducing costs.

MIMO is currently immersed in an ambitious project to invest in new models that cover a wider range of hemato-oncological diseases by improving its models, including the selective humanization of multiple therapeutic targets, as well as the development of new technologies that offer more, faster and better information to its clients.

Nanogrow Biotech

Small molecules, Big Solutions



BUSINESS SEGMENTS: Biopharma			
N° OF EMPLOYEES: 11-50			
HEALTHCARE	TECHNOLOGY	INNOVATION	BETTER FUTURE



Nanogrow is a pioneering biotechnology startup developing next-generation biologic therapies based on nanobodies, with the aim of transforming the pharmaceutical industry. Its mission is to create a new generation of biologic medicines that combine the efficacy of conventional antibodies with the precision and safety of localized administration, significantly reducing side effects while improving patient access to advanced therapies.

Nanobodies are the smallest naturally occurring antibody fragments, characterized by their simple structure and exceptional physicochemical stability. These unique properties enable targeted formulation and localized delivery, minimizing off-target effects in healthy tissues. Their small size also allows for superior tissue penetration, enabling the selective neutralization of disease-associated targets with high specificity and therapeutic efficacy.

Nanogrow’s proprietary platform integrates camelid-derived nanobodies, synthetic libraries, biophysical, biochemical, and computational characterization, artificial intelligence, and advanced formulation technologies. This comprehensive platform enables the rapid identification, optimization, and production of disease-specific nanobodies while streamlining development timelines and reducing costs. As a result, Nanogrow is positioned to deliver innovative therapeutic solutions with the potential to redefine the treatment of multiple diseases and establish itself as a global leader in nanobody-based therapeutics.

Nanogrow represents a unique opportunity for investors and strategic partners seeking to be at the forefront of biotechnology innovation. Backed by an internationally recognized scientific team and a strong commitment to disruptive therapeutic development, the company is well positioned to achieve significant clinical and commercial milestones, ultimately improving the lives of millions of patients worldwide.

New Pharma Solutions

Innovative Medicines



BUSINESS SEGMENTS: Biopharma and Services			
N° OF EMPLOYEES: 1-10			
R&D	SWEETS	GUMMIES	SOLUTIONS



New Pharma Solutions is a company focused on the development of innovative pharmaceutical forms, founded in 2019.

In recent years, the pharmaceutical industry has shown an increase in the development of innovative drugs that go beyond what other more traditional drugs offered.

At New Pharma Solutions, in addition to covering conventional dosage forms, they are specialized in innovative, more consumer-friendly dosage forms, such new approaches to drug development that ensure product viability and regulatory compliance.

Ojer Pharma

New technologies for a new skin



BUSINESS SEGMENTS: Biopharma			
Nº OF EMPLOYEES: 11-50			
INNOVATION	DERMATOLOGY	INTERNATIONAL	PATIENT-CENTERED



Ojer Pharma is a pharmaceutical company, spin-off of the University of Navarre, founded in 2005 with the aim of identifying therapeutic gaps in the dermatological market and developing innovative dermatological drugs and products for both human and veterinary use that meet the needs of patients all around the world.

Ojer Pharma directs all its efforts in the research and development of products that address skin diseases from a global perspective, which means, combined treatment of causes and symptoms. In this sense, Ojer Pharma has developed an innovative vehiculization technology in the form of transparent bioadhesive gels. After its application, the gel generates a film over the skin acting as a matrix for the sustained release of dermatological active ingredients (lipophilic and hydrophilic).

The development of this technology is mainly based on the concept of “patient-centred approach”, with the main objective of improving the safety and/or efficacy profiles of well-known drugs and improving patient adherence.

This technology has been successfully applied to three of the five best-selling dermatological molecules in the world, resulting in different medicines with significant competitive advantages, and it has been adequately protected through international patents.

CONTACT:



Palobiofarma

Innovation through medicinal chemistry



BUSINESS SEGMENTS: Biopharma		
Nº OF EMPLOYEES: 11-50		
NEW DRUG DISCOVERY AND DEVELOPMENT	MEDICINAL CHEMISTRY	ADENOSINE MODULATORS



Palobiofarma is a biotech company focused in the discovery and development of innovative medicines based on the modulation of the adenosine receptors.

Palobiofarma focused internal resources on areas where lies the experience of the management team:

- Virtual drug design
- Medicinal Chemistry
- In Vitro Pharmacology of adenosine
- Physico-chemical characterization of the compounds
- Intellectual Property

The remaining activities needed for the full compound characterization and the nomination of a development candidate, such as the pharmacology and toxicology tests, are carried out through partnerships with various companies (CROs), Research Centres and Universities.

CONTACT:



Qube Pharma Group

Innovation, added-value and technology for health and well-being



BUSINESS SEGMENTS: Biopharma, MedTech and Services	
Nº OF EMPLOYEES: 51-200	
ADDED-VALUE	DRUG DEVELOPMENT



Qube is a pharmaceutical group established in 2007 and formed by 4 companies (Geiser Pharma, Lozy's Pharmaceuticals, Sejmet Pharmaceuticals and Pharma Innovation)* that are dedicated to the research, development, licensing and manufacturing of value-added products in the following pharmaceutical areas, implementing advanced technologies and innovative pharmaceutical forms:

- Generic Niche Products
- OTC products
- CE Marked Medical Devices



Innovation, whether in the use of cutting-edge technologies in their developments, or in the form of new release systems, is a constant in the activity of the QUBE group companies, which is also reflected in the implementation of co-creation projects with companies from other sectors.

Its activity combines all the skills and experience necessary to cover the entire value chain (market research, R&D, registrations, manufacturing and supply) and to be able to offer unique products at a global level and drug developments to third parties.

It drives customer success and offers limited competition for successful product marketing.

CONTACT:



Recombina

Transforming the future through biotechnology



BUSINESS SEGMENTS: Biopharma			
Nº OF EMPLOYEES: 1-10			
BIOTECHNOLOGY	VACCINES	PROTEINS	BACTERIA



Recombina Biotech is a biotechnology company specialized in genetic engineering services and construction of custom recombinant microorganisms.

It offers innovative biotechnological solutions with applications across a wide range of sectors. Our focus lies in designing microorganisms "à la carte" that present new functionalities, with the final aim of improving existing processes or developing new ones. We are committed to advancing science and technology, especially in the fields of vaccines, biosensors, biomaterials, and therapies for various diseases.

Its highly trained and experienced team utilizes advanced genetic engineering techniques to manipulate and re-program microorganisms, tailoring them to the needs of each client.

Some of its services include:

- Construction of recombinant microorganisms
- Optimization of biotechnological processes
- Development of therapies and vaccines
- Advisory and consulting services for biotechnological projects

The technological character of Recombina has been recognized by the Government of Navarre as an innovative technological-based company of Navarre, and by the Spanish Ministry of Science and Innovation with the Innovative SME seal.

CONTACT:



Telum Therapeutics

The science of today is the technology of tomorrow



BUSINESS SEGMENTS: Biopharma			
Nº OF EMPLOYEES: 11-50			
BIOTECH	ANTIMICROBIALS	MULTIDRUG RESISTANCE	PHAGE THERAPY



Telum Therapeutics is a global drug discovery biotechnology company specializing in the use of Engineered Phage Lytic Proteins as new antimicrobial products.

Telum Therapeutics leverages the power of nature through the understanding of biological controls exerted by bacteriophages to balance bacterial ecosystems. Our technology is based on the extraction of bacterial strains from unexplored soil environments and the identification of bacteriophages, -lytic and lysogenic-, that prevail in those exotic bacterial populations.

This is the basis to develop unique phage libraries, providing us new avenues for the discovery and development of potent antibacterial agents using lytic phage enzymes as a new innovative tool to treat human infections diseases. Bacteriophage lysins have long been demonstrated to be effective enzybiotics in various infectious models.

Thanks to its modular structure, with at least two distinct domains (enzymatic hydrolysis and substrate recognition), we can combine the different modules and produce, through synthetic biology, new enzybiotics with desired properties, such as higher activity or a broader spectrum of destruction. Moreover, lysins can even be engineered to kill bacterial pathogens from without, a property that is not present in natural lysins.

CONTACT:



Plaza CEIN, Polígono Industrial Mocholí | 31110, Noáin, Navarra - España | www.telumtherapeutics.com | contact@telumtherapeutics.com | (+34) 644 024 097

Trimerbody Pharma

Molecular engineering for health



BUSINESS SEGMENTS: Biopharma			
Nº OF EMPLOYEES: 1-10			
IMMUNO ONCOLOGY	BISPECIFIC ANTIBODY	IMMUNOSTIMULATION	TUMOUR



Trimerbody Pharma is a biopharmaceutical company dedicated to the development of multivalent and multispecific therapeutic antibodies, called Trimerbodies. Its antibodies are the result of internal R&D and collaborations with leading research centres and prominent companies in the sector.

The company has multiple development programmes in various therapeutic areas, including immuno-oncology, a high-growth field for both companies and investors.

At Trimerbody Pharma, they develop next-generation antibodies for cutting-edge therapies against advanced cancers, with the aim of offering hope to future patients affected by cancers for which current treatments are insufficient.

Trimerbody® is a registered trademark and is covered by international patents.

CONTACT:



Plaza CEIN 5, Polígono Industrial Mocholi. | www.trimerbodypharma.com | marta.compte@trimerbodypharma.com | (+34) 626 647 778

V Labs Analytics

We are an analysis laboratory.
ISO 9001. GMP. FDA



BUSINESS SEGMENTS: Biopharma & Services

Nº OF EMPLOYEES: 1-10

QUALITY	INNOVATION	COMMITMENT	PROFESSIONALISM
---------	------------	------------	-----------------



V Labs Analytics

V Labs Analytics develops innovative analytical methods, adding value to healthcare companies and supporting them in their growth and diversification, offering them access to specialized technologies and knowledge.

Its Quality Management System is based on GMP, ICH, and ISO standards, ensuring compliance with all of them and guaranteeing the reliability, accuracy, and integrity of the information it handles and the results it provides.

CONTACT:

Plaza Cein 5, NAVE B8 – 31110 Noáin, Navarra, España | www.vlabsanalytics.es | abustamante@vlabsanalytics.com | +34 660 337 901



Abanza

A new era in soft tissue fixation



BUSINESS SEGMENTS: MedTech			
Nº OF EMPLOYEES: 1-10			
DEVICES	TRAUMATOLOGY	SOFT TISSUE	REPAIR



Abanza is a company specialized in the biomedical sector dedicated to research and technological development in the field of sports medicine.

Its main objective is the research and development of disruptive innovations in the field of sports medicine, with the aim of bringing them to the market.

Abanza develops new surgical techniques, implantable devices, and medical instruments with the mission of improving the results obtained with current procedures and devices through innovation. This provides doctors with the necessary tools to ensure faster and more effective rehabilitation for their patients.

The company began by focusing on achieving anatomically and functionally effective restoration of the Anterior Cruciate Ligament (ACL) of the knee. It has already developed a tibial fixation system for soft connective tissue and is in the process of developing devices for other parts of the body.

The company has a multidisciplinary and highly qualified technical team, combining medical and biomedical engineering knowledge, which guarantees the quality and reliability of the devices developed, offering the best care for the patient.

Agenor Mantenimientos

Hospitals in good shape



BUSINESS SEGMENTS: MedTech and Services			
Nº OF EMPLOYEES: 201-500			
CLINICAL ENGINEERING	ELECTROMEDICINE	MANAGEMENT	MEDICAL EQUIPMENT



Created in 1996, Agenor Mantenimientos is a family company with a solid structure established throughout Spain. It is dedicated to the management and maintenance of medical equipment. It works to ensure the optimal functioning of all medical devices in health centers.

It works to the needs of each organization, providing specific solutions in which engineering, equipment and logistics go hand in hand.

It currently has more than 260 professionals serving more than 200 client entities and managing more than 300,000 electromedical equipment.

Bioinnovación Dental

Precision, experience and service. In every implant, for every patient.



BUSINESS SEGMENTS: MedTech			
Nº OF EMPLOYEES: 11-50			
QUALITY	SERVICE	INNOVATION	KNOW-HOW



Bioinnovación Dental is a CAD/CAM dental manufacturing company. Founded in 2006, the company set out with a pioneering vision: to lead the digital transformation of the dental industry in Spain at a time when the sector was only beginning to explore the potential of CAD/CAM technology. Since then, Bioinnovación Dental has evolved alongside the most significant milestones in the field, consistently embracing the most innovative strategies and the most advanced tools and materials available — always guided by the same founding principle: that what we manufacture will become part of a person, and that person deserves nothing less than the best.

In 2026, Bioinnovación Dental expands its scope with the launch of BIDimplants, its biomedical division dedicated to the development of custom-made implants. The starting point is the personalised subperiosteal implant, a solution designed for patients with severe bone atrophy classified as Cawood & Howell IV, V or VI, who are not candidates for conventional endosseous implantology. BIDimplants is not simply an extension of our product portfolio: it represents a formal commitment to generating robust, prospective and unbiased long-term clinical evidence on the performance of these devices — in a field that has re-emerged with renewed momentum thanks to

advances in computed tomography (MSCT, CBCT), the full consolidation of digital workflows in dentistry, and laser-based additive manufacturing (LPBF), yet still lacks the longitudinal data it deserves.

What sets BIDimplants apart is not only the precision of the implant itself, but the follow-up framework built around it. Every device we manufacture is integrated into a prospective multicentre clinical registry that tracks real-world outcomes over time, identifies risk factors, refines design and production protocols, and provides the prescribing clinician with evidence that no product catalogue can replace. We manufacture the implant and we stay with the patient. That is what we mean when we say excellence doesn't expire.

Behind all of this is a multidisciplinary team that brings together dental technicians specialised in digital design and biomaterials, mechanical engineers with extensive expertise in machining strategies and metallurgy, and biomedical engineers with a strong background in implantology and complex clinical problem-solving. A company that has spent twenty years building expertise in the dental sector, and is now channelling that knowledge in service of the patients and professionals who seek solutions where others see only limitations.

CONTACT:

Polígono Mutilva, Calle V – Nave 24 – 31192 Mutilva, Navarra, Spain

www.bioinnovaciondental.com | info@bioinnovaciondental.com | (+34) 948 277 430



Creo Medical

Anything is Possible with the Right Approach



BUSINESS SEGMENTS: MedTech			
Nº OF EMPLOYEES: 201-500			
ENDOSCOPY	UROLOGY	URODINAMIC	GASTROSCOPY



The company was founded under the name Albyn Medical in Scotland and has been designing, manufacturing and supplying equipment and consumables to a global customer base since 1985, through an international network of distributors.

Its headquarters are currently located in Navarre (Spain), where it has production and distribution facilities, as well as a research and development centre.

From its inception, Albyn Medical has specialised in the manufacture and supply of systems and consumables for urology, gynaecology and gastroenterology, as well as in the distribution of products from other manufacturers within these fields to complement its product range.

It was one of the first companies in the world to develop computerised systems for urodynamics and gastrointestinal motility; Albyn Medical's ongoing R&D programme ensures that our products always meet the changing needs and specifications of the market.

Since its foundation in 1985, Albyn Medical has expanded its presence in the European market by acquiring ABS Medical in France, Wiest Uropower, Pauldrach Medical and Endo-Technik in Germany, Premier En-

doscopy in the UK and Boucart Medical in Belgium. In doing so, it has expanded its product portfolio and direct presence in Europe, building a resilient company that offers excellent service and support to customers.

Albyn Medical's product range encompasses diagnostic, therapeutic and hygiene products, as well as those designed to prevent cross-contamination, for clients such as hospitals, hospital groups and medical practices in both the public and private sectors. Its own brand of gastrointestinal products includes a range of biopsy forceps, loops, catheters, tubes and valves, as well as distributing a wide range of diagnostic and therapeutic endoscopy devices. Albyn Medical also offers a range of products for the cleaning, sterilisation and storage of endoscopes, as well as endoscopic accessories for hospitals.

In 2020, the Welsh-based company Creo Medical PLC acquired Albyn Medical and its European subsidiaries. As part of this process, Albyn Medical changed its name to its current name, Creo Medical SL.

In 2025, Micro-Tech Nanjing, a leader in the endoscopy sector, acquired a 51 per cent stake in Creo Medical SL and its subsidiaries.

CONTACT:

Pol. Ind. Comarca I C/A N°D22 | 31160, Orcoyen, Navarra – España

www.creomedical.com | (+34) 948 293 324



DARWIN Biomed®

Intelligent Robotics for Human Mobility



BUSINESS SEGMENTS: MedTech			
Nº OF EMPLOYEES: 1-10			
ROLLARSE	SMART AGEING	NEUROREHABILITATION	SILVER ECONOMY



DARWIN Biomed is a Navarra-based startup dedicated to intelligent robotics applied to human mobility. Its first product, MICHELANGELO, is a next-generation walker that combines biometric sensors, motorized assistance, and digital connectivity to help older adults walk with greater safety, confidence, and autonomy, anticipating risk situations such as falls or loss of balance.

The company was created to address a growing social and healthcare challenge: an aging population and the high number of falls among older adults, which lead to injuries, loss of independence, and a significant burden on healthcare systems. MICHELANGELO positions itself as a middle-ground solution between low-cost, low-tech traditional walkers and premium devices with very high price points, offering real innovation at an accessible price.

The business model is based on local manufacturing and commercialization through pharmacies, orthopedic stores, and specialized distributors, with an approach that also includes assisted living centers, insurance companies, and healthcare professionals as strategic allies to accelerate the product's adoption.

DARWIN Biomed is founded by a team with experience in industrial design and biomedical engineering, and is backed by a venture capital firm, a leading industrial partner, and public and private investors, who contribute capital, sector expertise, and industrialization and distribution capabilities.

CONTACT:



Data Value Management

Custom AI and software development tailored to clients' needs



BUSINESS SEGMENTS: MedTech & Services	
Nº OF EMPLOYEES: 1-10	
ARTIFICIAL INTELLIGENCE	SOFTWARE DEVELOPMENT



Data Value Management is dedicated to data analysis and Artificial Intelligence. To achieve this, it creates custom applications using open-source software, allowing clients to effectively leverage their data.

These applications address various challenges:

1. The company transforms data into relevant information for decision-making. This makes it possible to identify the key variables affecting different processes, their critical levels, the marginal impact of a modification, or the expected outcome.
2. It develops predictive systems. These systems provide precise foresight into the future, enabling companies to anticipate upcoming scenarios and take actions to achieve their desired results.
3. Task automation, which ensures that mechanical and repetitive tasks are performed automatically by software.
4. Computer Vision systems that enable image classification, defect detection in manufacturing processes, and more.

5. AI Chatbot development based on Generative AI. This allows companies to query any information using natural language, interacting with AI systems through their everyday speech.
6. Data visualization. This enables companies to query their data easily and agilely, increasing their understanding of what is happening in the business.

Additionally, DVM provides specialized training in data analysis and Artificial Intelligence.

The solutions developed by DVM are targeted at various sectors, but the company has extensive experience in the healthcare sector, where it has developed numerous client projects and participates in several R&D initiatives. It is worth noting that all solutions developed are based on open-source software and deployed on the clients' own servers. As a result, there are no licensing fees for using the developed system, security is guaranteed since they are hosted on-premise, and the client becomes the actual owner of the solution by having full access to the developed source code.

CONTACT:



Embega Healthcare

Flexible devices for better health



BUSINESS SEGMENTS: MedTech & Services			
Nº OF EMPLOYEES: 51-200			
CDMO	FLEXIBLE ELECTRONICS	MEDICAL DEVICES	INDUSTRIALIZATION



Embega Healthcare is the health unit of Embega, a cooperative within Mondragon Corporation, specializing in the design and industrialization of flexible electronics for medical devices. Based in Villatuerta (Navarra, Spain), it formally joined MONDRAGON Health in March 2026 as its tenth member cooperative, reinforcing its position within the group’s health ecosystem and its ties to the Navarra industrial base.

The company operates as a CDMO (Contract Development and Manufacturing Organization) for medical device manufacturers who need to transfer their design to an industrial partner capable of scaling production while meeting the quality and traceability standards required by the healthcare sector. Its value proposition centers on flexible and printed electronics applied to health: ECG/EEG systems, therapeutic electrodes, biosensors for measuring biomarkers (lactic acid, glucose, and others), sensorized insoles, and wearable devices.

Among its most notable milestones is the industrialization of a vest with integrated electrodes for arrhythmia detection, with 3D monitor visualization. The company also holds an AEMPS license and is currently working toward ISO 13485 certification, advancing toward the quality standards required by the medical device industry.

Embega Healthcare collaborates with private and public partners, in both R&D projects and market development and industrialization, supporting startups, scale-ups, technology centers, and established manufacturers from functional design through to series production. This collaboration network is rooted in Navarra’s healthcare and industrial ecosystem, with reach extending across the rest of Spain and Europe.

With a focus on population aging, remote patient monitoring, and home hospitalization, Embega Healthcare responds to the growing demand for connected devices that enable continuous health tracking, aligning with the “quantified self” trend toward the digitization of health data.

Erabaki 2010

Innovative spirit



BUSINESS SEGMENTS: MedTech	
Nº OF EMPLOYEES: 1-10	
INNOVATION IN DISPOSABLE MEDICAL DEVICES	



Erabaki 2010 is an SME that is dedicated to the development, manufacturing and import of disposable medical products that solve recurring problems in the hospital and operating room environment.

It specializes in protection of equipment and patients and normothermia.

They have 5 product areas:

- Floor, non-slip absorbent products for operating room and ante-operating room floors
- Surgical disposable products

- Non-woven fabric products
- Absorbent and waterproof products for the operating room table
- Dulet, an Ultralight Tactical Evacuation Device

The products it develops and manufactures are marketed under the Manaca Medical™ brand.

everSens

What your breath reveals



BUSINESS SEGMENTS: MedTech

Nº OF EMPLOYEES: 1-10

BIOMARKERS	EXHALED	RESPIRATORY HEALTH	INFLAMMATION
------------	---------	--------------------	--------------



Founded in Pamplona, Spain, Eversens is a leader in developing innovative solutions based on exhaled bio-marker analysis.

Its flagship product, the evernoa BASE device, represents a paradigm shift in respiratory health monitoring. This compact, user-friendly device allows individuals to assess their airway inflammation levels simply by exhaling into a mouthpiece. The evernoa BASE utilizes patented technology to detect nitric oxide (NO), a bio-marker closely associated with asthma and other respiratory conditions.

The simplicity and non-invasiveness of the evernoa BASE make it an ideal tool for both healthcare providers and individuals seeking personalized insights into their respiratory health. By regularly monitoring NO levels, individuals can proactively manage their symptoms, optimize medication compliance, and identify potential exacerbations early on.

Eversens’ commitment to innovation extends beyond diagnostic tool development. They are actively involved in research and development, exploring the potential of exhaled biomarkers to address a broader spectrum of health conditions. Their research aims to establish breath analysis as a reliable and accessible method for early disease detection, personalized treatment, and disease management.

Hemotic

Smart Blood Management



BUSINESS SEGMENTS: MedTech and Services

Nº OF EMPLOYEES: 1-10

DIGITAL HEALTH	BLOOD ESTABLISHMENTS	ADVANCED TECHNOLOGICAL SOLUTIONS	HEALTHCARE MANAGEMENT
----------------	----------------------	----------------------------------	-----------------------



At Hemotic, technological solutions that optimise the resources and processes of blood banks are developed; promoting the efficient use of an essential, scarce and perishable resource such as blood, and generating a positive and sustainable impact on society.

Hemotic offers innovative, secure, scalable and high-impact solutions to improve the efficiency, quality and sustainability of the transfusion system. Its technology does not replace healthcare professionals; it simply helps them make the best decisions at all times through highly intuitive and user-friendly solutions.

In 2022, LHEMA software was unveiled, one of the first applications of mathematics in the field of

transfusional medicine. LHEMA ensures the efficient management of blood and significant savings for the healthcare system, making sure that every drop counts.

In 2026, two new innovative solutions were brought to market, to continue contributing to the improvement of blood management in healthcare: the AN-HEMO software and the HEMOPOOL software. All of Hemotic products are developed in close collaboration with their clients, ensuring that every update and improvement stems from their suggestions and daily challenges.

Hemotic’s ongoing commitment to innovation is the key to continued growth and progress towards personalised transfusion medicine.

Hyssogenix

Odontology Genetic Lab



BUSINESS SEGMENTS: MedTech and Services		
Nº OF EMPLOYEES: 1-10		
LABORATORY	GENETICS	PERSONALISED DENTISTRY



Hyssogenix was created to provide the dentistry sector with the latest scientific advances in a practical and simple way for the dental professional.

Currently the company is very focused on periodontics. On the one hand, it carries out analysis of the main pathogenic bacteria present in the subgingival cavity in order to help the dentist in his treatment with the patient. It is very interesting to complement this analysis with the study of genetic predisposition, also to periodontal disease, which helps the dentist to know in advance the risk of suffering from chronic or acute periodontitis and thereby help prevent the progression of the disease.

Hyssogenix is working with two R&D projects on the oral microbiome and the importance of the beneficial bacteria found in a healthy mouth to be able to treat dysbiosis when they find a patient where there is an increase in pathogenic bacteria and a decrease in beneficial bacteria. The use of antibiotics, probiotics, prebiotics and postbiotics are the future of treatments for infections, not only in dentistry, but to prevent many other diseases related to dysbiosis of the human microbiota, such as vascular, neurodegenerative, or autoimmune diseases.

iAR



BUSINESS SEGMENTS: MedTech			
Nº OF EMPLOYEES: 11-50			
DEVELOPMENT	ADVANCED SOFTWARE	AI	AUGMENTED REALITY



Industrial Augmented Reality (iAR) is a company specialized in the development of customized industrial mobility software, using advanced technologies such as augmented reality, virtual reality and artificial vision.

The areas covered are the control and operation of equipment and machines, interactive management of technical documentation, maintenance management, process optimization and, in general, any industrial improvement activity.

The benefits derived from the use of this type of applications lie mainly in the savings, both in time and economic, as well as in the increase of user satisfaction, given the intuitive nature of its use. To this end, the company is formed by a multidisciplinary team that covers areas such as industrial consulting, software development and process automation with a clear customer orientation.

Insaight

Growing Intelligently



SEGMENTOS DE NEGOCIO: MedTech			
Nº DE EMPLEADOS: 1-10			
AI	BIOTECHNOLOGY	PHARMACEUTICALS	SYNTHETIC BIOLOGY



Insaight specializes in custom protein design through Artificial Intelligence. It is currently working to bring to market tailored protein design services for the pharmaceutical and biotechnology industries.

It also aims to complement its services with regulatory support and guidance throughout the biomolecule patenting process.

Its services focus on enabling their clients to manage their resources more efficiently, significantly reducing the costs and timelines of R&D processes for their protein-based products, and strengthening their business models by helping them bring biopharmaceuticals to market faster, at lower cost, and protected by patents with longer effective exploitation periods.

Since its founding in 2024, Insaight has been developing its Artificial Intelligence platform. At present, it consists of several key components: StructureGPT and the XSeq systems.

- StructureGPT is a Generative Pretrained Transformer that maps a protein’s structure to its sequence. It has two main capabilities: generativity and inpainting. Generativity allows it to associate a single protein structure with multiple sequences that either preserve the original function but have improved man-

ufacturability (stability, solubility, expression in cells), or offer enhanced functional properties (e.g., higher catalytic activity in enzymes, greater affinity and/or specificity in antibodies, etc.). Inpainting allows StructureGPT to redesign parts of a protein, or even design it from scratch, accelerating the development of complex molecules like chimeric receptors (CAR-T), or enabling the design of ad hoc proteins for challenges where no natural candidates exist.

- The XSeq systems are a family of AI models that evaluate the sequences generated by StructureGPT and filter them, enabling the selection of those best suited to the client’s problem. This is possible because each XSeq model predicts a property related to the sequence, which defines its name. For example, $\Delta\Delta G_{Seq}$ predicts the thermodynamic stability ($\Delta\Delta G$) of a protein based on its sequence.

Together, this platform enables the generation and selection of improved versions of its clients’ proteins. However, Insaight knows this is not enough. Its clients need assurance that its designs will work in the lab. For this reason, it is working to establish an experimental laboratory that will allow the company to test its designs and transfer only those that are proven to work.

Medical Open World

Where you are born should not decide whether you live



BUSINESS SEGMENTS: MedTech			
Nº OF EMPLOYEES: 1-10			
INCUBATORS	OPEN SOURCE	NEONATAL HEALTH	GLOBAL IMPACT



Medical Open World is a non-profit organization that develops accessible medical technology to reduce neonatal mortality in low-resource and fragile settings. We were created around a simple but urgent belief: a premature baby’s chances of survival should not depend on where they are born. Based in Pamplona, we work with an international network of collaborators, hospitals, and NGOs, following a hands-on approach designing, manufacturing, deploying, and supporting solutions that truly work where infrastructure is limited.

Our flagship project is IncuNest, an open-source, low-cost neonatal incubator designed to deliver essential care where conventional incubators are financially out of reach. With an approximate material cost of €350, IncuNest combines thermoregulation, phototherapy, and remote monitoring, aiming to provide thermal stability and practical clinical safety through a robust, portable, and energy-efficient design. In many hospitals, continuous Kangaroo Mother Care is not always

feasible due to staffing constraints, distance, shift dynamics, or family realities. IncuNest fills that critical gap by keeping the newborn warm and stable when the mother cannot be present.

Sustainable impact is built into the way we operate. We manufacture in Spain with the support of solidarity workshops and vocational training centers, and we collaborate with logistics partners and local organizations so that delivery is followed by real installation and training—not just shipment. In parallel, we publish documentation so other teams can replicate, adapt, and improve the technology, accelerating collective learning and scaling impact beyond our own capacity.

We are actively looking for partnerships with health-care, industrial, and R&D organizations willing to contribute expertise, clinical validation, manufacturing, certification, field deployment, or logistics.

MyVitale

Physical Activity – Nutrition – Wellness



BUSINESS SEGMENTS: MedTech and services			
Nº OF EMPLOYEES: 11-50			
HEALTH COACH	PHYSICAL ACTIVITY	NUTRITION	PERSONALISATION



MyVitale: Transforming Health Management with Innovative Technology

MyVitale is a leading technology company based in Navarra, pioneering the creation of digital solutions that enable proactive and personalized health management, with a special focus on chronic diseases such as diabetes, obesity, cancer, and active aging. Its platform offers highly personalized physical activity and nutrition programs, designed to improve patients' quality of life and optimize outcomes in the management of these conditions.

What sets the company apart is its ability to adapt each health program to the individual needs of every user, using artificial intelligence (AI) to ensure continuous and real-time personalization. Its AI platform analyses health data and patient habits, automatically adjusting exercise and nutrition programs to maximize their effectiveness. This data-driven approach not only im-

proves health outcomes but also facilitates long-term adherence to treatment, a critical challenge in chronic disease management.

In addition to personalized programs, MyVitale has two key components: the mobile app for patients and the professional platform for doctors, nutritionists, and trainers. Healthcare professionals can monitor patient progress, make real-time adjustments, and create personalized health plans, all through an integrated system. This enables continuous, tailored care that enhances treatment efficacy and facilitates prevention.

Its business model is scalable and based on various revenue streams, including B2B2C, white-label licensing, and outcome-based models. Its technology is accessible and integrates with third parties through APIs and SDKs. With a solid user base and a proven track record of growth, MyVitale is well-positioned to expand its presence in the global digital health market.

NNBi 2020 SL

Turning Data into Intelligent Decisions



BUSINESS SEGMENTS: MedTech			
Nº OF EMPLOYEES: 11-50			
ARTIFICIAL INTELLIGENCE	DATA SCIENCE	DIGITAL HEALTH	SMART INDUSTRY



NNBi is a company specialized in artificial intelligence, data science, and advanced software development for the healthcare and industrial sectors. Our mission is to transform complex data into actionable knowledge that helps organizations optimize processes, improve decision-making, and generate measurable impact.

We combine mathematical modelling, artificial intelligence, software development, and data integration to create innovative solutions tailored to each client's needs. Our multidisciplinary team includes AI specialists, mathematicians, engineers, software developers, physicians, and pharmacologists, enabling us to address complex challenges from a comprehensive and results-oriented perspective.

In healthcare, we collaborate with hospitals, research centers, foundations, and pharmaceutical companies on projects related to personalized medicine, clinical prediction, clinical trial optimization, biomedical data

analytics, and digital medical device development. In industry, we apply advanced artificial intelligence techniques to optimize production processes, improve energy efficiency, implement predictive maintenance systems, and support data-driven decision-making.

One of NNBi's key differentiators is our commitment to security and quality. We hold ISO 27001 certification and comply with the Spanish National Security Framework (ENS) at High Level, ensuring the highest standards of information security, cybersecurity, privacy, and data governance. These certifications enable us to deploy solutions in highly regulated and demanding environments, providing customers with maximum confidence when managing critical information and digital transformation projects.

Opportunity Health

Medical innovation to save lives



BUSINESS SEGMENTS: MedTech			
Nº OF EMPLOYEES: 1-10			
INNOVATION	HEALTH	SAFETY	EMERGENCY



Opportunity Health S.L. is an innovative company in the medical device sector, dedicated to safety and well-being.

Our flagship product, Yarnasa, is an automatic and self-applicable anti-choking device designed to save lives in choking emergencies.

Its mission is to reduce accidental choking deaths through accessible, effective, and easy-to-use tech-

nology. The company is backed by key investors such as Easo Ventures and Sodena, and collaborates with prestigious institutions like the University of Navarra and the Santiago de Compostela Health Research Institute, supporting the validation and preclinical trials of Opportunity.

It is continuously developing solutions to reach global markets, prioritizing innovation and accessibility.

Orisnova

Built on Precision



BUSINESS SEGMENTS: MedTech			
Nº OF EMPLOYEES: 1-10			
INVISIBLE ORTHODONTICS	CLINICAL PRECISION	INNOVATION	ENGINEERING



Orisnova is a laboratory specialising in the design and manufacture of custom clear aligners, created to support dentists and orthodontists in invisible orthodontic treatments through a clinical, technological and aesthetic approach. The company brings together senior professional experience, applied engineering, medical expertise and a quality culture focused on precision, safety and predictability in every treatment plan.

Its working model integrates a medical department, an engineering team and technical specialists who collaborate closely with the clinic, from digital diagnosis through manufacturing. Based on a 3D scan and an individual assessment of each malocclusion, every treatment plan is thoroughly reviewed by a specialised dentist or orthodontist. This clinical supervision supports direct discussion with the prescribing professional, helps refine dental movements and makes it possible to select the therapeutic approach best suited to the agreed objectives.

Manufacturing relies on high-performance transparent materials, latest-generation international dental equipment and highly precise digital processes. The aim is to deliver comfortable, discreet and durable aligners with an individually tailored fit and carefully controlled finish. Orisnova complements the product with digital resources, technical support and professional follow-up, helping clinics manage cases more efficiently and reduce avoidable treatment time, always under the clinical judgement of the dentist or orthodontist responsible for the patient.

Among its solutions, OrisnovaActive stands out as a staged follow-up method that introduces new assessments, impressions and adjustments whenever clinically appropriate. This approach enables the treatment to respond to the patient's actual progress, minimise unforeseen deviations and strengthen the precision of the final outcome. With more than 15 years of combined professional experience, Orisnova works in support of oral health and smile aesthetics, offering clinics a close professional relationship, specialised advice and advanced technology. Its value proposition is built on clinical excellence, responsible innovation and comprehensive personalisation for every patient.

ORP – Online Rehabilitation Program

Regaining your balance changes everything



BUSINESS SEGMENTS: MedTech			
Nº OF EMPLOYEES: 1-10			
SOFTWARE	TECHNOLOGY	VESTIBULAR	MEDICAL DEVICES



ORP – Online Rehabilitation Program is a digital device specialized in vestibular rehabilitation, currently undergoing certification as a Medical Device, designed to transform the way patients with balance and vestibular system disorders access quality treatments. It was born with the mission of bringing specialized rehabilitation to anyone, regardless of their geographic location, breaking down the access barriers that have traditionally limited this type of therapy to large hospitals or highly specific clinics.

The company has its own technology team working continuously on the development and improvement of its platform, giving it full control over the innovation, evolution, and quality of its product. This proprietary technology combines the clinical rigor of vestibular rehabilitation with the advantages of telemedicine, offering healthcare professionals and patients a reliable, precise tool adapted to the real needs of remote

treatment. In addition, it has its own algorithm fed by constant data generated in each rehabilitation session, allowing it to continuously refine its model, personalize treatments, and grow its technology on an increasingly solid foundation of real-world evidence.

At ORP, vestibular health is considered to deserve the same attention and technological investment as other medical specialties. That is why the company works hand in hand with clinical professionals to ensure that every feature of its device meets real medical criteria, resulting in a tool that combines innovation with safety and demonstrable clinical efficacy from its earliest stages of development.

Its goal is clear: to grow both nationally and internationally, establishing itself as a benchmark in digital vestibular rehabilitation. Being part of the Navarra Health Cluster represents a strategic opportunity to connect with other entities in the health ecosystem, share knowledge, and accelerate its growth, always with Navarra as the base of its technological development.

OSF Plastic

Specialists in plastic injection moulding and liquid silicone solutions



BUSINESS SEGMENTS: MedTech			
Nº OF EMPLOYEES: 11-50			
INJECTION	MEDICAL PLASTIC	MEDICAL SILICONE	CLEAN ROOM



OSF Plastic is a specialist in the manufacture of plastic and liquid silicone injection (LSR) parts. With a history of more than twenty-five years, we offer our services to a wide range of industries, including the healthcare, automotive, electrical and industrial fields.

OSF distinguishes by its efficiency, rigor and openness to collaboration with other companies. It maintains agile and direct communication with its customers, without intermediaries and guaranteeing a transparent and effective process at all times. It has an integrated high-tech infrastructure and a highly qualified human team, which allows it to place its products and services in the field of excellence.

For the manufacturing of medical and pharmaceutical parts, it has an ISO 7 certified Clean Room and has established rigorous action protocols to guarantee the cleanliness and sterility of the environment.

Its facilities, equipment and experience allow the company to satisfy the classification requirements of the products to be manufactured and comply with the applicable regulations in each case.

Tairel Data

Cutting-Edge Artificial Intelligence, Real Results



BUSINESS SEGMENTS: MedTech

Nº OF EMPLOYEES: 1-10

MACHINE LEARNING

DEEP LEARNING

ARTIFICIAL INTELLIGENCE

TAIREL DATA

As data scientists, the company’s focus is clear: trans-forming complex data ecosystems into decision-mak-ing environments. It applies statistical and mathemati-cal sciences to the development of Artificial Intelligence solutions.

It ensures data privacy is maintained throughout the processes, and that the company makes the decisions, with solutions designed specifically for each client using rigorous mathematical and statistical principles.

• **AI Models:** It creates and trains custom AI models for the most complex problems or R&D environments. Experts in Machine Learning and Deep Learning tech-niques applicable to:

- **Industry** (computer vision, quality control, predictive maintenance, supply chain optimization, technical document processing, etc.).
- **Science** (structural biology, medicine, materials science, chemistry, particle physics, etc.).
- **SMEs** (customer service, demand forecasting, inventory management, etc.).

- **Data Engineering:** It builds robust and scalable in-frastructures that guarantee your information is always available, clean, and ready to use.
- **Advanced and Predictive Analytics:** It uses statistical models to anticipate trends, customer behavior, and operational risks.
- **Generative and Applied Artificial Intelligence:** It integrates the latest AI innovations to optimize internal processes and improve the user experience, always with an ethical and results-oriented approach.

Tecnimoem Care

We’re about much more than products: we find solutions



BUSINESS SEGMENTS: MedTech

Nº OF EMPLOYEES: 51-200

SERVICE

MANUFACTURER

DEPENDENCY

SOLUTIONS

tecnimoem care

Tecnimoem Care manufactures social and health care products. And, yes, it manufactures to the highest qual-ity standards, with the most demanding certifications, guarantees and licences established by the European Community.

So it isn’t just products that come out of Tecnimoem Care’s production centres. It provides solutions to im-prove the quality of life of dependent and vulnerable people and their families, as well as the working condi-tions of their caregivers and all the people and compa-nies that trust its brand.

Range
Tecnimoem Care produces:

- **BEDS:** Homecare and nursing home beds. Wide range from basic versions to Alzheimer’s beds and ultra-low profile beds. Solutions for medical mattresses.

- **HOISTS:** Homecare and nursing home beds. Transfer hoists and standing hoists.
- **COMMODE CHAIRS:** Bath and shower chairs. Various solutions designed for the hygiene of elderly people.

- It offers:**
- **FLEXIBILITY:** To adapt to the customer’s needs by customising products or developing new ones.
 - **CAPACITY:** To undertake large-scale projects or those with great potential for growth and expansion.
 - **INNOVATION:** To respond to any customer needs, adapting current models or developing new ones.

TedCas

Naturalizing technology



BUSINESS SEGMENTS: MedTech			
Nº OF EMPLOYEES: 1-10			
TRACEABILITY	HUMANISATION	GESTURE AND VOICE CONTROL	SOFTWARE



TedCas is a telecommunications company laser-focused on making the interaction between people and technology feel natural. In the healthcare realm, we streamline the way medical staff interacts with technology in operating rooms to enhance patient care and surgical precision.

From its inception, TedCas has been driven by the vision of streamlining and optimizing processes through innovative solutions. It has developed an extensive array of tools and services, spanning from voice and gesture control to remote equipment management.

At TedCas, they have crafted groundbreaking solutions tailored for the healthcare sector. Its goal is to make life easier for healthcare professionals by automating tasks wherever possible. It offers voice-controlled systems to streamline interactions with medical equipment, data

management tools to streamline workflows in hospitals and clinics, smart calendars for hospital logistics management, and its flagship product, the “VEGA” system, for remote equipment control in telemedicine and remote technical support.

Its commitment to innovation and research is at the core of TedCas. It works closely with partners and clients to deliver customized solutions that tackle the unique challenges of each case. With a team of top-notch professionals and a solid reputation in the market, TedCas remains at the forefront of technology, revolutionizing how people engage with the digital realm.

Viscofan

Reshaping food and wellbeing. For many, for long.



BUSINESS SEGMENTS: MedTech			
Nº OF EMPLOYEES: > 1.000			
COLLAGEN	SCAFFOLDS	3D BIOINKS	BIOMATERIALS



Founded in 1975, Grupo Viscofan is a world leader in the manufacture and distribution of packaging for the food industry. It has its own technological development in cellulose, collagen, fibrous and plastic and an outstanding worldwide presence that allows the company to distribute its products to more than 100 countries on all continents.

In addition to technological innovation, excellence in customer service, cost efficiency and commitment to sustainability are the pillars on which its daily work is based. This work is carried out by more than 5,300 employees of 60 nationalities whose commitment and know-how provide the differential value on which Viscofan’s future is built.

Viscofan is the first company in the sector to join the United Nations Global Compact for the achievement of the Sustainable Development Goals of the 2030

Agenda, contributing mainly to the following goals: SDG 2 Zero Hunger, SDG 3 Health and Wellbeing, SDG 6 Clean Water and Sanitation, SDG 8 Decent Work and Economic Growth, SDG 12 Responsible Consumption and Production, SDG 13 Climate Action.

In addition to the casings sector, Viscofan also provides solutions and products in other areas related to access to nutrition and wellness. It has developed other products such as tubular plastics solutions, packaging and third parties, new edible casings, functional solutions and nutra-medical-pharma products. In addition to this diversification activity, the company wants to use its know-how as a catalyst for innovations to expand into new markets with attractive growth trends in the field of food, wellbeing and health.

Vitio

Early detection of patients at risk



BUSINESS SEGMENTS: MedTech			
Nº OF EMPLOYEES: 15			
MONITORING	TEMPERATURE	WEARABLE	REMOTE



Vitio Medical is a medical device manufacturer specializing in solutions for the remote monitoring of patients. The company develops and manufactures products designed to support healthcare professionals in the remote monitoring of non-critical patients, both at home and in healthcare settings.

Its mission is to empower patients and healthcare professionals by providing the best user experience at all levels and processes, developing medical devices that allow patients to be monitored in real time and remotely in a simple, safe and cost-competitive way.

One of the company’s key products is a Class IIa certified software platform that enables healthcare professionals to remotely monitor a range of patients’ health parameters, facilitating ongoing patient follow-up and management. In addition, Vitio develops and manufactures a wearable medical device for continuous body temperature monitoring.

Ysium Medical

Healthcare technology – Innovation for a better future



BUSINESS SEGMENTS: MedTech			
Nº OF EMPLOYEES: 11–50			
HEALTHCARE	TECHNOLOGY	INNOVATION	BETTER FUTURE



Ysium Medical is a technology-based company that uses engineering to design and develop medical devices that meet the needs of both healthcare personnel and patients. It designs manufacturing-oriented and regulatory-ready medical devices.

Ysium Medical works innovating through design and engineering hand in hand with healthcare personnel, to solve the needs of current unsolved problems and create new medical devices. It ensures the arrival to their practices through the transfer to the main Medtech companies in the medical sector with established sales channels and global reach.

It focuses on improving the well-being and quality of life of the patient and all the people around and we humanize technology to put it at the service of people. It facilitates the work of healthcare professionals by creating easy, intuitive, ergonomic, user-friendly tools and comfortable workflows.

Ysium Medical creates devices for different stages of a pathology (prevention, diagnosis, treatment and rehabilitation) and applies a rigorous project selection criteria (ideas from health professionals with entrepreneurial spirit and market needs), to choose products that solve a real and relevant need present in a large number of people.



Asphalion

Knowledge from Experience



BUSINESS SEGMENTS: Services			
N° OF EMPLOYEES: 51-200			
REGULATORY	SAFETY	MEDTECH	PHARMACEUTICAL



Asphalion is an international Regulatory, Scientific & Safety consultancy company with offices in Barcelona, Madrid, Munich and London. Founded in 2000, Asphalion has grown consistently and currently employs over 180 team members of over 16 different nationalities.

Its strong track record has made Asphalion a reference in the international healthcare sector and a key stakeholder in the implementation of new regulatory standards. Asphalion’s experts have delivered solutions to over 1,000 Pharmaceutical, Biotechnological and Medical Technology companies from more than 50 countries in over 5,000 projects covering non-clinical and clinical development, CMC, dossier writing, regulatory procedures, vigilance, eSubmissions and data manage-

ment for both medicinal products and medical devices. Asphalion offers strategic advice, expert consulting, operational support, as well as full outsourcing services for all types of products in all therapeutic areas.

To deliver the best possible solution in each project, Asphalion works closely with international competent authorities, notified bodies, scientific associations and key opinion leaders and maintains a comprehensive network of geographic and functional partners.

Conasa

Technology as a Service For People



BUSINESS SEGMENTS: MedTech and Services			
N° OF EMPLOYEES: 201-500			
TECHNOLOGY	INNOVATION	PROXIMITY	EFFICIENCY



Conasa helps companies and public administrations address their technological challenges through reliable, innovative solutions tailored to their real needs. As part of the Cibernos Group, it has a solid track record of supporting our clients throughout their digital transformation, technological modernisation and operational improvement processes. Its goal is to put technology at the service of people and turn it into a practical tool for improving efficiency, driving competitiveness and enabling organisations to evolve.

It offers a broad portfolio of services covering custom software and application development, infrastructure, systems and communications management, cloud services, cybersecurity, process automation, artificial intelligence, data analytics, technical support and managed services. This comprehensive approach enables the company to undertake projects of varying complexity and support its clients throughout the entire solution lifecycle: consulting, design, implementation, maintenance, evolution and support.

It also has extensive expertise in the eHealth sector, gained through its experience in technology projects for hospitals, healthcare centres, health profession-

als and public administrations. It provides specialised products and solutions that help digitise care processes, improve the management of clinical information and enable more efficient, secure and personalised healthcare. It applies technologies such as artificial intelligence, interoperability, advanced analytics and secure data management to address the sector’s current challenges, always paying particular attention to data protection, regulatory compliance and the experience of both patients and professionals.

It stands out for its close approach, flexibility and ability to understand each client’s business and specific context. It does not simply implement technology: it analyses every need and develop realistic, scalable and results-oriented solutions. Choosing Conasa means working with a solid, accessible and forward-looking technology partner, supported by specialised, multidisciplinary teams that combine sector expertise, technological knowledge and commitment. Conasa believes innovation only creates real value when it improves processes, makes people’s work easier and contributes to achieving each organisation’s objectives.

EAA Med Consulting

Driving innovation through regulatory excellence



BUSINESS SEGMENTS: Services				
Nº OF EMPLOYEES: 1-10				
MEDICAL DEVICES	STRATEGY	REGULATION	QUALITY	AI



EAA Med Consulting is a consultancy specialized in medical devices, supporting manufacturers, start-ups, and healthcare companies throughout the entire product lifecycle. It helps transform innovative ideas into compliant medical devices ready to enter international markets.

Its expertise includes regulatory strategy, technical documentation under the European Medical Device Regulation (EU) 2017/745 (MDR), ISO 13485 quality management systems, ISO 14971 risk management, clinical evaluation, usability engineering, Software

as a Medical Device (SaMD), cybersecurity, and compliance with international standards. It also supports companies in defining regulatory pathways for both the European and U.S. markets.

EAA Med Consulting works closely with organizations of all sizes, from startups developing their first medical device to established manufacturers seeking additional regulatory or quality expertise. Its goal goes beyond compliance, it helps companies use regulatory strategy as a business enabler, reducing development risks and accelerating market access.

Koümer

We equip your lab for success



BUSINESS SEGMENTS: Services			
Nº OF EMPLOYEES: 1-10			
QUALITY	ADAPTABILITY	PROFESSIONALISM	EXPERIENCE



Since 1993, Koümer has been dedicated to providing the highest quality laboratory furniture solutions. With over three decades of experience in the market, it has established a standard of excellence and precision that sets us apart in the industry. Its mission is to equip laboratories with furniture that not only meets the highest quality standards but is also designed to enhance the efficiency and safety of scientific work environments.

Customization is one of its core values. It understands that every laboratory has unique needs, so it offers tailored solutions to meet the specific requirements of each client. Its team of experts works closely with clients to design and manufacture furniture that fits perfectly with their operational and spatial needs. In addition to its focus on quality and customization, it also takes pride in its proximity and speed of service.

Its customer service team is always available to assist and advise at every stage of the process, from conceptualization to installation.

NASERTIC

Talent, Infrastructures, Technology and Services,
by the people and for the people



BUSINESS SEGMENTS: Services			
Nº OF EMPLOYEES: 51-200			
INFRASTRUCTURE	SEQUENCING	SUPERCOMPUTING	SYNTHETIC BIOLOGY



NASERTIC (Navarra de Servicios y Tecnologías S.A.) – a company within the Navarre Public Business Corporation Group (CPEN), and a public entity belonging to the Government of Navarre – provides bespoke services through the intelligent integration of infrastructure and services in telecommunications, information technologies, supercomputing, and laboratory services: high-throughput sequencing, genomic and bioinformatic analyses, physicochemical, agri-food, forensic, and toxicological testing.

NASERTIC employs more than 170 highly qualified professionals. It is a hub of knowledge, specialisation, and experience; a key enabler for strategic projects; and a bridge between the Government and the people of Navarre. It operates with an open outlook, flexibility, and agility.

Since 2025, NASERTIC has managed IRIS Lab, the experimental laboratory of the Digital Innovation Hub, IRIS Navarre. Among other infrastructures and facilities,

it includes molecular and synthetic biology laboratories, high-throughput genomic sequencing platforms (NGS), nucleic acid design and synthesis, procedure automation, cell culture, protein expression, production, purification and characterisation, as well as computing and bioinformatics capabilities.

NASERTIC also manages the VIDAAS Centre – an Advanced and Innovative Centre for Active and Healthy Autonomous Development. This social innovation lab, promoted by the Government of Navarre, aims to enhance autonomy and quality of life for individuals by implementing new networked approaches to develop tailored solutions to emerging collective challenges.

Sumanlab

Integral services for your laboratory



BUSINESS SEGMENTS: Services		
Nº OF EMPLOYEES: 1-10		
COMPREHENSIVE LABORATORY SOLUTIONS	PROXIMITY	PERSONALIZED ADVICE



Sumanlab is the entrepreneurial result of the synergy of several professionals with more than 20 years of experience in the manufacturing and distribution of technical furniture and laboratory equipment.

It has qualified people to design and manufacture its own product, provide excellent commercial attention, guarantee compliance with legal and quality standards, organize logistics and installation and provide close after-sales assistance.

It currently manufactures with its own resources under the Irulab brand name technical laboratory furniture,

culture and drying ovens, thermostatic baths, vapor and particle filtration cabinets, vertical and horizontal laminar flow cabinets and fume extraction fume hoods. It specialises in the management and complete development of the project in all its phases: consulting, design, planning and execution.

In addition, in order to provide an integral supply solution, it has distribution agreements with manufacturers of equipment, consumables and laboratory reagents.



Auxilab

Quality, assistance and experience: more than 45 years being your guarantee of confidence in laboratory equipment



BUSINESS SEGMENTS: Distribution			
Nº OF EMPLOYEES: 11-50			
LABORATORY EQUIPMENT	QUALITY	COMPETITIVENESS	SPEED



Since 1976, Auxilab has been pioneer in Spain in the distribution of laboratory materials and equipment. Over the years, it has established a reputation for excellence, providing a constant and growing service. It stands out for offering one of the widest ranges of items for laboratories through an extensive network of specialised distributors.

Quality products for all sectors where there is a laboratory: education, research, health, pharmaceutical industry, agri-food, among others. It has our own brands that guarantee excellent value for money, and its distributes prestigious international brands with local stock.

Its spacious and modern facilities, with more than 6000 m2 of storage space, house an extensive stock available for immediate delivery, with more than 14,000 references in stock. In addition, it offers pre-sales technical support by qualified personnel and it has its own Technical Assistance Service (TAS) for the repair and maintenance of equipment.

Committed to quality, Auxilab operates under an ISO9001:2015 certified management system, audited by AENOR since 1999, and its international presence extends to more than 80 countries.

Disayt

Redefining the standard in pharmaceutical logistics



BUSINESS SEGMENTS: Distribution			
Nº OF EMPLOYEES: 201-500			
LOGISTICS	TRANSPORT	FLEXIBILITY	TECHNOLOGY



Disayt is a Navarra logistics company that includes among its strategic products a powerful Pharma division specialized in the pharmaceutical sector, with more than 40 years of experience in managing the supply chain for leading national laboratories.

Disayt Pharma offers its clients a personalized and tailored logistics service for the entire operation of stock management, preparation, and distribution of orders. It provides warehouse and transport solutions based on the product characteristics or the recipients, complying with the demanding regulations of the sector.

Disayt Pharma ensures national and international coverage of its services, controlled by intelligent logistics tools that allow real-time visibility, monitoring the temperature of the merchandise in each phase of the supply chain, from procurement to delivery to the final recipient.

Nafarco

Always close to you



BUSINESS SEGMENTS: Distribution		
Nº OF EMPLOYEES: 51-200		
DISTRIBUTION	SERVICES	PHARMA CHANNEL



Nafarco, a pharmaceutical cooperative, was founded in 1959 by a group of pharmacists from Navarre. Our main objective is to act in the healthcare field by offering comprehensive services for pharmacies, providing solutions to improve competitiveness, profitability and enhancing the healthcare role of the pharmacist. Nafarco currently has a staff of 75 people, 390 member pharmacies and 130 clients.

Facilitating pharmacy access to medications and other products sold in pharmacies has been Nafarco’s main service since its establishment. The objective of Nafarco’s merchandise supply service is to make all authorized medications available to all pharmacies in Navarre, in addition to the widest possible range of health and parapharmacy products.

To this end, and complying with the Distribution Good Practices necessary to carry out this activity, it has 17,614 m² of facilities in Noáin-Pamplona. More than 40,000 units leave daily, distributed across 30 routes throughout Navarre.

Sanifarma

Pharmacies at your service



BUSINESS SEGMENTS: Distribution			
Nº OF EMPLOYEES: 1-10			
PHARMA	GROUP	HEALTH	SERVICES



Sanifarma is a consortium of pharmacies with over 20 years of experience, dedicated to offering innovative services in the field of health and wellness. Currently, it operates in Navarre, Guipúzcoa, and La Rioja.

Its mission is to enhance people’s quality of life and promote healthy habits through various health campaigns and prevention programs.

Furthermore, Sanifarma provides its affiliated pharmacies with tools tailored to enhance their competitiveness and customer loyalty. It excels in procurement management and negotiation with suppliers, category management, as well as in sales training and consultancy.

Among its services aimed at fostering customer loyalty, it offers a loyalty card, a weekly medication organizer, its quarterly Health and Wellness magazine, dermocosmetic and hair care advisory services, and health campaigns.

Index of associated entities within the value chain:

	Knowledge and R&D	11
	Business segments	21
	Care	81
	Adacen	82
	Clínica Universidad de Navarra	83
	Colegio Oficial de Enfermeras de Navarra	84
	Colegio Oficial de Farmacéuticos de Navarra	85
	Colegio de Médicos de Navarra	86
	IDEA Living lab	87
	IdiSNA	13
	Mutua Navarra	88
	Stakeholders	91

Care



Adacen

Innovation and care for a new life



CARE			
Nº OF EMPLOYEES: 51-200			
BRAIN DAMAGE	NEUROREHABILITATION	RESEARCH	FAMILY SUPPORT



ADACEN, Navarra Brain Damage Association, is a non-profit organization dedicated to improving the quality of life for individuals affected by acquired brain injury and their families in Navarre. Founded in 1994, the association has become a key reference in the field of neurological rehabilitation, offering a wide range of specialized services and comprehensive support.

ADACEN's focus is on providing personalized care through a multidisciplinary team including neuropsychologists, physiotherapists, occupational therapists, speech therapists, and social workers. This care is aimed not only at physical and cognitive recovery but also at the emotional and social well-being of the patient and their family, recognizing the complexity of the impact that brain damage can have on all aspects of life.

Among the services offered by ADACEN are physical and cognitive rehabilitation, psychological support, social integration activities, and training and awareness programs aimed at the general community. Additionally, ADACEN promotes research and development of new methodologies and technologies that can contribute to improving treatments and the quality of life of affected individuals.

CONTACT:



Clínica Universidad de Navarra

Patient-centered



CARE			
Nº OF EMPLOYEES: > 1.000			
ASSISTANCE	RESEARCH	TEACHING	EXCELLENCE



The Clínica Universidad de Navarra is the hospital of the University of Navarre. With over 3.400 professionals working exclusively at its headquarters in Pamplona and Madrid, the Clínica Universidad de Navarra is a leading academic and research hospital in the sector of personalised medicine, according to the Anglo-Saxon model.

Created in 1962, it is a medical-hospital center characterized by its high degree of medical specialization, its constant technological renovation, and its teamwork, which allows a multidisciplinary and personalized assessment of each patient.

Research, teaching and assistance are carried out together with the Faculties of Medicine, Science and Pharmacy, the School of Nursing and the Center for Applied Medical Research (CIMA).

CONTACT:



Colegio Oficial de Enfermeras de Navarra

The value of caring



CARE	
Nº OF EMPLOYEES: 1-10	
PROFESSIONAL DEVELOPMENT AND REGULATION	RESEARCH AND INNOVATION
CONTINUING PROFESSIONAL DEVELOPMENT (CPD)	CARE



COLEGIO OFICIAL DE ENFERMERAS DE NAVARRA
NAFARROAKO ERIZAINEN ELKARGO OFIZIALA

The Official College of Nurses of Navarre (COENAV), is a public-law corporation established in 1918. In accordance with its Statutes, its primary objectives are:

- To serve as the sole institutional representative of the nursing profession, safeguarding its integrity and defending the professional interests of registered members, including the prevention of professional intrusion.
- To protect the rights and interests of consumers and users of nursing services, as well as those of registered nurses.
- To ensure the highest standards of quality in the professional practice of nursing in Navarre, and to collaborate actively in the operation, promotion, and improvement of the healthcare system.
- To guarantee that the activities of its members always comply with the ethical standards of the nursing profession and with the requirements of the society they serve.
- To cooperate with the Public Administrations of Navarre.

COENAV currently represents approximately 6,000 nurses and operates two headquarters: one in Pamplona and another in Tudela. The College offers its members a broad range of services, including:

- Professional development through continuing education and the organization of seminars and events
- Scholarships
 - Conferences and congresses
 - Postgraduate programmes (master's degrees, specialist qualifications, and diplomas)
 - Doctoral studies
 - Research placements
 - Development cooperation projects
- Research Observatory
- International Cooperation Department
- Support with the processing of the Professional Career pathway
- Professional Liability Insurance
- Legal advisory services

CONTACT:



Colegio Oficial de Farmacéuticos de Navarra

Empowering pharmacists to reach their full potential in healthcare, focusing on patient requirements



CARE			
Nº OF EMPLOYEES: 11-50			
REPRESENTING THE PHARMACEUTICAL PROFESSION	HEALTH PROMOTION	TRAINING	EXCELLENCE



The Official College of Pharmacists of Navarre (COFNA) has been representing all pharmacists practicing in the Community of Navarre for more than 125 years.

Founded in 1899, COFNA works to defend the pharmaceutical profession and all professionals practicing in the region, as well as to ensure that its members practice their profession to the highest standards. In this way, it watches over the rights of its members and the rights of patients. Thus, it organizes activities and services of interest to its members; guarantee professional ethics and dignity and respects the rights of individuals.

Currently, about 1,600 pharmacists are registered in the region of Navarre. All of them work to promote public health and prevent disease from different healthcare areas: Pharmacies, Hospital Pharmacy, Clinical Analysis, Pharmaceutical Industries, Academia, Distribution and Research.

The entire pharmaceutical profession responds to major health and social challenges affecting the health of the population, such as drug supply problems, a shortage of health professionals, the aging of the population, unwanted loneliness, depopulation, growing mental health problems or public health risks and new epidemics.

Pharmacists are a fundamental and key profession in strengthening the health system of the Autonomous Community of Navarre, and COFNA is the entity in charge of ensuring the correct practice of the profession and defending the rights of all professionals.

CONTACT:



Colegio de Médicos de Navarra

To represent, defend and support the medical profession and its professionals



CARE
Nº OF EMPLOYEES: 10-50



REPRESENTING AND DEFENCE OF DOCTORS	MEDICAL ACT MANAGEMENT	DEONTOLOGY
-------------------------------------	------------------------	------------

The Medical Association of Navarre was created in 1898 following the approval of the Royal Decree on the Statutes for the Regime of Medical Associations on 12th April, which established membership as a compulsory requirement for professional practice. With a history of more than 100 years, the Medical Association of Navarre currently has more than 4,500 members.

The mission of the Medical Association of Navarre is to: represent, defend and support the medical profession and its professionals; guarantee the development of an ethical and quality medical practice open to society; and provide service with the objective of training, promoting and supporting the professional development of its members.

The Medical Association is defined as an entity itself, useful for professional development, close to the collegiate, representative and guarantor of the independence of the medical act. It is a reference in management, collegiate services and application of ethical standards and health opinion.

Transparency, ethics, commitment, effectiveness and efficiency, respect and responsibility are the main values on which the Medical Association of Navarre is based.

The two main functions entrusted by the legislator are: to represent all the doctors of Navarre before any instance and to watch over the independence of the medical act and the ethical and technical quality of the same, whoever pays for it.

In short, the Medical Association of Navarre is entrusted with the role of independent guarantor of fundamental individual rights such as the right to health and the right to life, which are clearly implied in the medical act.

IDEA Living Lab

Innovation and Gerontology



CARE



BUSINESS SEGMENTS: Services

Nº OF EMPLOYEES: 201-500

LIVING LAB	GERONTOLOGY	INNOVATION	GERONTOTECHNOLOGY
------------	-------------	------------	-------------------



IDEA is a SME company, with international projection with more than 15 years of experience specializing in the promotion and management of centers, programs and social-health services for the elderly, families and professionals.

Its strategic lines are: research, healthcare innovation, specialized consulting and training.

Idea currently manages 14 centers in Spain, including residences, daily centers, home help and supervised apartments. It has a vocational, transdisciplinary team, and most of them are university professors specialized in the field of gerontology.

IDEA manages the only Living Lab specialized in gerontology in Spain, and certified by the European Network of Living Labs.

It participates in national and European projects, related to the promotion of active aging, gerontechnology, silver market and attention to chronicity and fragility. In its Living Lab, it accompanies technological entities in the launch of products to the market, from phases TRL1 to TRL 9, defining use cases, based on co-creation and co-design with future users/clients, piloting, testing validation, and determination of business models.

It has developed Campus by IDEA, a center of excellence in care from which it seeks to train professionals in this sector, with generative and multimodal training (classroom and online) seeking that users grow in skills and gain practical tools.

Mutua Navarra



CARE

Nº OF EMPLOYEES: 51-200



OCCUPATIONAL HEALTH	ABSENTEEISM	TECHNOLOGY	MUTUAL INSURANCE COMPANY
---------------------	-------------	------------	--------------------------

Mutua Navarra is a mutual insurance company that collaborates with the Social Security and was founded in 1905. Since then, it has been working to ensure the occupational health of the workforces of its member companies. Its purpose is to work for sustainable wellbeing by helping people to feel better. It provides health, welfare and sustainability to workers and companies and manages resources and social benefits in a responsible and efficient way, focused on excellent results.

Mutua Navarra is part of the state public sector and, like other mutual insurance companies, does so under the aegis of the Ministry of Security, which has entrusted it to manage several social benefits: occupational accidents and occupational diseases, economic benefits for incapacity for work due to common contingency, risk of pregnancy and breastfeeding, child care due to serious illness and cessation of business of self-employed workers.

Mutua Navarra has six branches throughout Navarra (Pamplona, Estella, Tudela, San Adrián, Alsasua and Bera), has more than 5,000 associated companies and

provides coverage to more than 120,000 people, which represents 40% of the people affiliated to Social Security in Navarre. It has more than 190 professionals, including over half of those working in the health sector. Mutua Navarra's objective is to recover its patients optimally in the shortest possible time thanks to work based on scientific evidence and medical protocols. It is an expert in occupational health (traumatology, rehabilitation, radiodiagnosis, ...) and has the best technical and human resources in Navarre.

It also offers advice to member companies in order to help them reduce absenteeism and occupational accidents by implementing specific action plans generated through personalized and accurate analysis of the data presented by each organization. It also has a line of advice on health promotion at work that seeks to disseminate healthy lifestyle habits in the workplace.

CONTACT:



Stakeholders



Index of associated entities within the value chain:

	Knowledge and R&D	11
	Business segments	21
	Care	81
	Stakeholders	91
	CEIN	92

CEIN

High-impact entrepreneurship



STAKEHOLDERS			
Nº OF EMPLOYEES: 10-50			
ENTREPRENEURSHIP	INCUBATORS	STARTUPS	CEIN HEALTH



The Business Innovation Center of Navarra (CEIN) is the reference entity in Navarre for the support of high impact entrepreneurship and scaling innovative startups.

It is a public company of the Government of Navarre whose objective is to promote the economic development of our territory. And it does so by promoting entrepreneurship, supporting the creation of new companies and boosting business growth.

CEIN activates entrepreneurial talent in strategic areas and in universities, generators of technology and knowledge.

It accelerates innovative business projects, with ambition for growth, unique and differentiated.

It helps innovative startups in their scaling and leap into new markets.

All this, with the collaboration of its entrepreneurship ecosystem.

For health entrepreneurship, CEIN launched the CEIN Health program, which supports, promotes and accelerates innovative entrepreneurship projects and startups in the health field in their business configuration, market launch and commercial development through first-class services and professionals.

CONTACT:







NHC

NAVARRA
HEALTH
CLUSTER

NAVARRA

Una forma de funcionar
Our own way